SCHEMBL6733639

SCHEMBL6733639

N/C(=N/O)c1ccc(CNC(=O)[C@@H]2CCc3cnc(NCCc4ccccn4)c(=O)n32)cc1

nearest known ligand 0.45

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
F2 P00734 19/20 0.45
F7 P08709 3/20 0.45
F3 P13726 3/20 0.45
PRSS1 P07477 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6733644 1.00 F2 (0.45) F2F7F3PRSS1
SCHEMBL6732975 0.84 F2 (0.45) F2F7F3PRSS1
SCHEMBL6732980 0.84 F2 (0.45) F2F7F3PRSS1
SCHEMBL6738663 0.82 F2 (0.49) F2PRSS1
SCHEMBL6733337 0.81 F2 (0.58) F2PRSS1
SCHEMBL6739800 0.80 F2 (0.49) F2PRSS1
SCHEMBL6740598 0.79 F2 (0.46) F2PRSS1
SCHEMBL6738372 0.79 F2 (0.47) F2PRSS1
SCHEMBL7298438 0.79 F2 (0.66) F2PRSS1
SCHEMBL6990916 0.79 F2 (0.63) F2PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6686358-B2 ANTICOAGULANTS; CARDOVISCULAR DISORDERS LES LABORATOIRES SERVIER (FR) 2004-02-03 US claimed
EP-1215213-A2 Bicyclic amino-pyrazone derivatives, their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2002-06-19 EP claimed
US-6686358-B2 ANTICOAGULANTS; CARDOVISCULAR DISORDERS LES LABORATOIRES SERVIER (FR) 2004-02-03 US disclosed
US-20020111341-A1 Bicyclic amino-pyrazinone compounds LES LABORATOIRES SERVIER (FR) 2002-08-15 US disclosed
EP-1215213-A2 Bicyclic amino-pyrazone derivatives, their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2002-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111341-A1 Bicyclic amino-pyrazinone compounds CTRL, PRSS3, PRSS1 F2 125/4885F7 1465/4885F3 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.